50
Participants
Start Date
December 21, 2018
Primary Completion Date
June 9, 2021
Study Completion Date
June 9, 2021
Biological: M254
M254 administered as intravenous infusion
Placebo
Placebo administered as intravenous infusion
Intravenous immunoglobulin (IVIg)
IVIg administered as intravenous infusion
Policlinico Universitario Agostino Gemelli, Roma
Debreceni Egyetem Klinikai Kozpont, Debrecen
Ucl de Mont-Godinne, Yvoir
Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvár
Pecsi Tudomanyegyetem, Pécs
Duke University Medical Center, Durham
Hosp. Regional. Carlos Haya, Málaga
Hosp. Gral. Univ. J.M. Morales Meseguer, Murcia
Lakes Research, Miami Lakes
University of South Florida, St. Petersburg
Hosp Clinico Univ de Salamanca, Salamanca
Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia
Taussig Cancer Insititute Cleveland Clinic, Cleveland
Hosp. Univ. Dr. Peset, Valencia
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola
Azienda Unita Sanitaria Locale di Ravenna, Ravenna
Ospedale 'Casa Sollievo della Sofferenza' - U.O. Ematologia-, San Giovanni Rotondo
University of Southern California, Los Angeles
Oncology Institute of Hope and Innovation, Whittier
Universitair Medisch Centrum Groningen, Groningen
PRA Health Sciences, Groningen
Silesian Healthy Blood Clinic, Chorzów
Samodzielny Publiczny Szpital Kliniczny Nr 1, Lublin
Szpital Wojewodzki w Opolu, Opole
Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSW w Poznaniu im prof Ludwika Bierkowskiego, Poznan
Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu, Wroclaw
Hosp Univ Vall D Hebron, Barcelona
Hosp. Univ. de Burgos, Burgos
Lead Sponsor
Momenta Pharmaceuticals, Inc.
INDUSTRY